Walleye Capital LLC Has $4 Million Stock Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Walleye Capital LLC has reduced its stake in Vaxcyte, Inc. by 29%, selling 43,190 shares during the first quarter, leaving it with 105,966 shares valued at approximately $4 million.
• Other institutional investors have increased their positions in Vaxcyte, with Wellington Management Group boosting its stake by 44.4%, now owning over 6.4 million shares valued at $242 million.
• Vaxcyte's stock has a current average rating of "Buy" from analysts, with a consensus target price of $136.50, despite reporting a quarterly loss that missed estimates.

Walleye Capital LLC lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 29.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,966 shares of the company's stock after selling 43,190 shares during the period. Walleye Capital LLC owned approximately 0.08% of Vaxcyte worth $4,001,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers boosted its position in shares of Vaxcyte by 5.5% in the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock worth $6,843,000 after buying an additional 9,416 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Vaxcyte by 5.8% in the first quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company's stock worth $362,000 after buying an additional 524 shares during the period. Parallel Advisors LLC boosted its position in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after buying an additional 1,071 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Vaxcyte by 75.4% in the first quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company's stock worth $3,648,000 after buying an additional 41,517 shares during the period. Finally, Assetmark Inc. boosted its position in shares of Vaxcyte by 1,758.8% in the first quarter. Assetmark Inc. now owns 14,424 shares of the company's stock worth $545,000 after buying an additional 13,648 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded up $0.02 during mid-day trading on Monday, reaching $30.79. The company had a trading volume of 944,896 shares, compared to its average volume of 1,511,927. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The stock has a market capitalization of $4.00 billion, a PE ratio of -7.49 and a beta of 1.04. The stock's 50 day moving average is $33.34 and its 200-day moving average is $42.17.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period last year, the business earned ($1.10) EPS. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.